Articles On Cardiex (ASX:CDX)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

Recce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the ASX!   Recce to expand diabetes foot ulcer Phase 1/2 trial An independent Safety Committee h...

Stockhead’s Top 10 at 10, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

14 million raise for CardieX consisted of a placement, shareholder entitlement offer, and a funding commitment agreement. Placement was cornerstoned by Regal Funds Management. C2 Ventures, the investment vehicle of the company’s CEO and ch...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in the red Small caps led by NickelSearch and Biotron A positive lead from Wall Street overnight didn’t sell well on local markets, which were...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

  ASX 200 find 0.5% to start the week, LTR looks ready to sell Energy stocks and miners offset IT and Consumer Discretionary losses Small cap winners led by EMD and GLH   Local markets were led higher on Monday, supported by resource busi...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

ASX 200 closes about 0.06% in the green (so, really, we ended in the chartreuse) down -1.2 in August Telco and IT Sectors offset Staples and Energy losses Small cap winners include 29M, CDX and HLA   Volatility, uncertainty and indecisio...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown   Despite the recent rally, the ASX Healthcare Index (XHJ) is...

Stroke has long been recognised as being among Australia’s most costly disease groups.  It occurs when a blood vessel supplying blood to the brain either suddenly becomes blocked or ruptures and begins to bleed which can result in part of t...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

The S&P ASX 200 was down 2.5% in May, with mid caps performing the best and small caps lagging blue chips The S&P ASX 200 Information Technology sector performed the best in May, up 11.6% following strong AI interest Wildcat Resou...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

The benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win the day, while InfoTech (-1.20%) takes a body blow. Lincoln Minerals (ASX:LML) tops the charts, up 36% for absolutely no reason at all.   Loc...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Equities research shop MST Access has upgraded its valuation on CardieX after the leading cardiovascular medtech’s world’s first, customizable vascular biometric monitor received regulatory clearance to provide medical grade arterial heart...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The world’s first, customisable vascular biometric monitor has received regulatory clearance to provide medical grade arterial heart health metrics to patients and clinicians. The CONNEQT Pulse arterial health monitor, has received 510(K) c...

CardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first multi-use vascular biometric monitor  Three ASX biotechs received clearance to commence studies   Health devices and wearables tech company Ca...

ASX 200 benchmark closes 0.11% lower after a fickle day on the bourse Iron ore price drops to five month lows, making (almost) everyone sad Larvotto ends up on top of the Small Caps, adding 61.9% for the day   Aussie markets were a tad me...

Australian Medtech CardieX has completed a $4.5million placement, continuing the company’s progress in positioning itself for a potential dual listing on a US exchange. Led by C2 Ventures, the investment vehicle of CardieX (ASX:CDX) CEO Cra...

ASX slumps even lower after lunch to end the day down around 0.5% China’s demands for the return of “weather balloon” debris met with hearty Pentagon chuckles Terramin’s bid to reopen a sub-winery mine shut down by the SA government   It’...

RBA lifts rates 25 basis points, says there’s more where that came from ASX immediately sags 0.5% on news from the Reserve Bank Federal Court finds in favour of Nuix over former CEO’s $183 million claim   The ASX has had a choppy old day,...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX puts on a late spurt to finish the day up 0.5% Star Entertainment and Bluescope in very hot water  Patriot Lithium grows 95% on stunning debut, because… lithium. Obviously. Welp… that’s it for the final day of the week, and as te...

Highlights The ASX 200 benchmark index closed in the green today (December 9), gaining 36.10 points or 0.50% to end at 7,211.60 points. Over the last five days, the index has lost 1.23% and 2.34% over the last 52 weeks. Materials was...

CardieX (CDX) subsidiary ATCOR pens a new clinical trial services agreement for its XCEL devices and data management servicesATCOR’s products and services will be used in a clinical trial to determine arterial health outcomes for the assess...

ASX 200 down 0.41% on lower than normal volume  Small cap index falls 1.17% and 7 out 11 sectors finish lower RBA raises the cash rate by 25 basis points to 3%   The ASX200 was down 0.41% today. The ASX Emerging Companies (XEC) index was...

Well… that was Tuesday, everyone. We trust you’ve had a great day, and hope that the whims of the Market Gods mean that you’ve managed to dodge the let-downs and can still put your hand in your pocket to pay for a pizza when you get home. B...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Medtech CardieX has successfully ruled off a $4.33 million placement to fast track the commercialisation of the company’s dual blood pressure and arterial health monitoring technology, the CONNEQT Pulse. CardieX (ASX:CDX) has been strongly...

Health technology company CardieX (CDX) raises $4.33 million under its placement and launches a $1 million share purchase plan (SPP) The placement funds were raised through the issue of more than 14.43 million shares to directors, domestic...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Literally every sector had a red month, but mining was the worst PayGroup gets surprise $120m takeover offer from US unicorn Deel Tempest Minerals signed JV to explore near the Karara Magnetite Iron mine June was a month of global econom...

CardieX (CDX) and its manufacturing partner, Andon, submit its blood pressure and arterial health monitor, CONNEQT Pulse, to the US Food and Drug Administration (FDA) Subject to FDA clearance, Pulse will be the first arterial health monito...